FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972912013> ?p ?o ?g. }

• W1972912013 endingPage "2087" @default.
• W1972912013 startingPage "2081" @default.
• W1972912013 abstract "Purpose To report the success rate, adverse events, and long-term prognosis of selective ophthalmic arterial injection (SOAI) therapy for intraocular retinoblastoma. Design Noncomparative case series. Participants A total of 408 eyes of 343 patients. Methods Retrospective chart review of patients with intraocular retinoblastoma treated with SOAI using a balloon catheter and melphalan between 1988 and 2007. Main Outcome Measures The technical success rate of SOAI (we defined success as the successful injection of melphalan into the ophthalmic artery), ocular adverse events, systemic adverse events, secondary neoplasms, eye survival, and visual acuity. Results Selective ophthalmic arterial injection was successful in 1452 procedures of 1469 trials, and the success rate was 98.8%. Each eye received 1 to 18 rounds of SOAI. Two eyes (0.5%) developed severe orbital inflammation, and 2 eyes (0.5%) had diffuse chorioretinal atrophy. Transient periocular swelling or redness occurred in some cases. No severe systemic adverse events were detected. Transient bronchospasm occurred in 1 patient (0.3%), and transient vomiting occurred in several patients. Twelve secondary neoplasms occurred in 11 patients, and the cumulative incidence was 1.3% at 5 years, 4.8% at 10 years, and 5.8% at 15 years. The eye preservation rate was 100% in group A, 88% in group B, 65% in group C, 45% in group D, and 30% in group E according to the International Classification of Intraocular Retinoblastoma. Fifty-one percent of eyes had a visual acuity >0.5, and 36% of eyes had a visual acuity >1.0 at the last follow-up examination in cases without macular tumors. Conclusions Selective ophthalmic arterial injection using a balloon catheter and melphalan achieved a success rate of 98.8% and was associated with few severe adverse events, including secondary neoplasms. More than half of the treated eyes were preserved, and more than half of the eyes without macular tumors maintained a visual acuity >0.5. Selective ophthalmic arterial injection is an established treatment method. We did not detect severe eye damage or severe systemic events; secondary neoplasms were seen but no more frequently than would otherwise have been expected. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. To report the success rate, adverse events, and long-term prognosis of selective ophthalmic arterial injection (SOAI) therapy for intraocular retinoblastoma. Noncomparative case series. A total of 408 eyes of 343 patients. Retrospective chart review of patients with intraocular retinoblastoma treated with SOAI using a balloon catheter and melphalan between 1988 and 2007. The technical success rate of SOAI (we defined success as the successful injection of melphalan into the ophthalmic artery), ocular adverse events, systemic adverse events, secondary neoplasms, eye survival, and visual acuity. Selective ophthalmic arterial injection was successful in 1452 procedures of 1469 trials, and the success rate was 98.8%. Each eye received 1 to 18 rounds of SOAI. Two eyes (0.5%) developed severe orbital inflammation, and 2 eyes (0.5%) had diffuse chorioretinal atrophy. Transient periocular swelling or redness occurred in some cases. No severe systemic adverse events were detected. Transient bronchospasm occurred in 1 patient (0.3%), and transient vomiting occurred in several patients. Twelve secondary neoplasms occurred in 11 patients, and the cumulative incidence was 1.3% at 5 years, 4.8% at 10 years, and 5.8% at 15 years. The eye preservation rate was 100% in group A, 88% in group B, 65% in group C, 45% in group D, and 30% in group E according to the International Classification of Intraocular Retinoblastoma. Fifty-one percent of eyes had a visual acuity >0.5, and 36% of eyes had a visual acuity >1.0 at the last follow-up examination in cases without macular tumors. Selective ophthalmic arterial injection using a balloon catheter and melphalan achieved a success rate of 98.8% and was associated with few severe adverse events, including secondary neoplasms. More than half of the treated eyes were preserved, and more than half of the eyes without macular tumors maintained a visual acuity >0.5. Selective ophthalmic arterial injection is an established treatment method. We did not detect severe eye damage or severe systemic events; secondary neoplasms were seen but no more frequently than would otherwise have been expected." @default.
• W1972912013 created "2016-06-24" @default.
• W1972912013 creator A5009400248 @default.
• W1972912013 creator A5049544529 @default.
• W1972912013 creator A5058997514 @default.
• W1972912013 creator A5080961958 @default.
• W1972912013 date "2011-10-01" @default.
• W1972912013 modified "2023-10-17" @default.
• W1972912013 title "Selective Ophthalmic Arterial Injection Therapy for Intraocular Retinoblastoma: The Long-Term Prognosis" @default.
• W1972912013 cites W2018748331 @default.
• W1972912013 cites W2045388751 @default.
• W1972912013 cites W2049929214 @default.
• W1972912013 cites W2059933096 @default.
• W1972912013 cites W2067611128 @default.
• W1972912013 cites W2069339449 @default.
• W1972912013 cites W2074511633 @default.
• W1972912013 cites W2078578521 @default.
• W1972912013 cites W2078839964 @default.
• W1972912013 cites W2085122535 @default.
• W1972912013 cites W2091827914 @default.
• W1972912013 cites W2095191852 @default.
• W1972912013 cites W2131044772 @default.
• W1972912013 cites W2212840843 @default.
• W1972912013 doi "https://doi.org/10.1016/j.ophtha.2011.03.013" @default.
• W1972912013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21715012" @default.
• W1972912013 hasPublicationYear "2011" @default.
• W1972912013 type Work @default.
• W1972912013 sameAs 1972912013 @default.
• W1972912013 citedByCount "185" @default.
• W1972912013 countsByYear W19729120132012 @default.
• W1972912013 countsByYear W19729120132013 @default.
• W1972912013 countsByYear W19729120132014 @default.
• W1972912013 countsByYear W19729120132015 @default.
• W1972912013 countsByYear W19729120132016 @default.
• W1972912013 countsByYear W19729120132017 @default.
• W1972912013 countsByYear W19729120132018 @default.
• W1972912013 countsByYear W19729120132019 @default.
• W1972912013 countsByYear W19729120132020 @default.
• W1972912013 countsByYear W19729120132021 @default.
• W1972912013 countsByYear W19729120132022 @default.
• W1972912013 countsByYear W19729120132023 @default.
• W1972912013 crossrefType "journal-article" @default.
• W1972912013 hasAuthorship W1972912013A5009400248 @default.
• W1972912013 hasAuthorship W1972912013A5049544529 @default.
• W1972912013 hasAuthorship W1972912013A5058997514 @default.
• W1972912013 hasAuthorship W1972912013A5080961958 @default.
• W1972912013 hasConcept C104317684 @default.
• W1972912013 hasConcept C118487528 @default.
• W1972912013 hasConcept C126322002 @default.
• W1972912013 hasConcept C141071460 @default.
• W1972912013 hasConcept C158846371 @default.
• W1972912013 hasConcept C185592680 @default.
• W1972912013 hasConcept C188261085 @default.
• W1972912013 hasConcept C197934379 @default.
• W1972912013 hasConcept C2776406671 @default.
• W1972912013 hasConcept C2776577112 @default.
• W1972912013 hasConcept C2777104736 @default.
• W1972912013 hasConcept C2778257484 @default.
• W1972912013 hasConcept C2780662894 @default.
• W1972912013 hasConcept C2781092963 @default.
• W1972912013 hasConcept C2781242345 @default.
• W1972912013 hasConcept C55493867 @default.
• W1972912013 hasConcept C71924100 @default.
• W1972912013 hasConceptScore W1972912013C104317684 @default.
• W1972912013 hasConceptScore W1972912013C118487528 @default.
• W1972912013 hasConceptScore W1972912013C126322002 @default.
• W1972912013 hasConceptScore W1972912013C141071460 @default.
• W1972912013 hasConceptScore W1972912013C158846371 @default.
• W1972912013 hasConceptScore W1972912013C185592680 @default.
• W1972912013 hasConceptScore W1972912013C188261085 @default.
• W1972912013 hasConceptScore W1972912013C197934379 @default.
• W1972912013 hasConceptScore W1972912013C2776406671 @default.
• W1972912013 hasConceptScore W1972912013C2776577112 @default.
• W1972912013 hasConceptScore W1972912013C2777104736 @default.
• W1972912013 hasConceptScore W1972912013C2778257484 @default.
• W1972912013 hasConceptScore W1972912013C2780662894 @default.
• W1972912013 hasConceptScore W1972912013C2781092963 @default.
• W1972912013 hasConceptScore W1972912013C2781242345 @default.
• W1972912013 hasConceptScore W1972912013C55493867 @default.
• W1972912013 hasConceptScore W1972912013C71924100 @default.
• W1972912013 hasIssue "10" @default.
• W1972912013 hasLocation W19729120131 @default.
• W1972912013 hasLocation W19729120132 @default.
• W1972912013 hasOpenAccess W1972912013 @default.
• W1972912013 hasPrimaryLocation W19729120131 @default.
• W1972912013 hasRelatedWork W112648410 @default.
• W1972912013 hasRelatedWork W1997497837 @default.
• W1972912013 hasRelatedWork W2045949360 @default.
• W1972912013 hasRelatedWork W2139788749 @default.
• W1972912013 hasRelatedWork W2398117356 @default.
• W1972912013 hasRelatedWork W2413606651 @default.
• W1972912013 hasRelatedWork W2951528829 @default.
• W1972912013 hasRelatedWork W3159940600 @default.
• W1972912013 hasRelatedWork W3169246243 @default.
• W1972912013 hasRelatedWork W32061794 @default.
• W1972912013 hasVolume "118" @default.
• W1972912013 isParatext "false" @default.
• W1972912013 isRetracted "false" @default.

• next